Dan T. Vogl

Dan T. Vogl

Auto-generated profile, based on publicly available information

Dan T. Vogl

Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2015 in Nature Medicine
Verified
Journal Article
Open access
PDF file
ARAaron P Rapoport
Aaron P Rapoport
ESEdward A Stadtmauer
Edward A Stadtmauer
GBGwendolyn K Binder-Scholl
Gwendolyn K Binder-Scholl
OGOlga Goloubeva
Olga Goloubeva
DVDan T Vogl
Dan T Vogl
CJCarl H June
Carl H June
Carl June and colleagues report the results of a phase I/II trial of adoptively transferred engineered T cells in patients with advanced multiple myeloma. Despite recent therapeutic advances, multiple myeloma (MM) remains largely incurable. Here we report results of a phase I/II trial to evaluate the safety and activity of autologous T cells engineered to express an affinity-enhanced T cell receptor (TCR) recognizing a naturally processed peptide shared by the cancer-testis antigens NY-ESO-1 and LAGE-1. Twenty patients with antigen-positive MM received an average 2.4 × 109 engineered T cells 2 d after autologous stem cell transplant. Infusions were well tolerated without clinically apparent cytokine-release syndrome, despite high IL-6 levels. Engineered T cells expanded, persisted, trafficked to marrow and exhibited a cytotoxic phenotype. Persistence of engineered T cells in blood was inversely associated with NY-ESO-1 levels in the marrow. Disease progression was associated with loss of T cell persistence or antigen escape, in accordance with the expected mechanism of action of the transferred T cells. Encouraging clinical responses were observed in 16 of 20 patients (80%) with advanced disease, with a median progression-free survival of 19.1 months. NY-ESO-1–LAGE-1 TCR–engineered T cells were safe, trafficked to marrow and showed extended persistence that correlated with clinical activity against antigen-positive myeloma.

29 April 2019 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
ACAdam Cohen
Adam Cohen
AGAlfred L. Garfall
Alfred L. Garfall
ESEdward A. Stadtmauer
Edward A. Stadtmauer
JMJ. Joseph Melenhorst
J. Joseph Melenhorst
SLSimon F. Lacey
Simon F. Lacey
MMMichael C. Milone
Michael C. Milone
Background: Chimeric antigen receptor (CAR) T cells are a promising therapy for hematologic malignancies. B-cell maturation antigen (BCMA) is a rational target in multiple myeloma (MM). Methods: We conducted a phase I study of autologous T cells lentivirally-transduced with a fully-human, BCMA-specific CAR containing CD3ζ and 4-1BB signaling domains (CART-BCMA), in subjects with relapsed/refractory MM. Twenty-five subjects were treated in 3 cohorts: 1) 1-5 x 108 CART-BCMA cells alone; 2) Cyclophosphamide (Cy) 1.5 g/m2 + 1-5 x 107 CART-BCMA cells; and 3) Cy 1.5 g/m2 + 1-5 x 108 CART-BCMA cells. No pre-specified BCMA expression level was required. Results: CART-BCMA cells were manufactured and expanded in all subjects. Toxicities included cytokine release syndrome and neurotoxicity, which were grade 3-4 in 8 (32%) and 3 (12%) subjects, respectively, and reversible. One subject died at day 24 from candidemia and progressive myeloma, following treatment for severe CRS and encephalopathy. Responses (based on treated subjects) were seen in 4/9 (44%) in cohort 1, 1/5 (20%) in cohort 2, and 7/11 (64%) in cohort 3, including 5 partial, 5 very good partial, and 2 complete responses, 3 of which were ongoing at 11, 14, and 32 months. Decreased BCMA expression on residual MM cells was noted in responders; expression increased at progression in most. Responses and CART-BCMA expansion were associated with CD4:CD8 T cell ratio and frequency of CD45RO-CD27+CD8+ T cells in the pre-manufacturing leukapheresis product. Conclusion: CART-BCMA infusions with or without lymphodepleting chemotherapy are clinically active in heavily-pretreated MM patients. Trial Registration: NCT02546167. Funding: University of Pennsylvania-Novartis Alliance and NIH.

19 May 2014 in Autophagy
Verified
Journal Article
Closed access
DVDan T Vogl
Dan T Vogl
ESEdward A Stadtmauer
Edward A Stadtmauer
KTKay-See Tan
Kay-See Tan
DHDaniel F Heitjan
Daniel F Heitjan
LDLisa E Davis
Lisa E Davis
RARavi K Amaravadi
Ravi K Amaravadi
The efficacy of proteasome inhibition for myeloma is limited by therapeutic resistance, which may be mediated by activation of the autophagy pathway as an alternative mechanism of protein degradati...

24 January 2024 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
GGGuido Ghilardi
Guido Ghilardi
JFJoseph A. Fraietta
Joseph A. Fraietta
JGJames N. Gerson
James N. Gerson
VDVivianna M. Van Deerlin
Vivianna M. Van Deerlin
JMJennifer J. D. Morrissette
Jennifer J. D. Morrissette
MRMarco Ruella
Marco Ruella

1 December 2011 in The Lancet Oncology
Verified
Journal Article
Closed access
AKAmrita Krishnan
Amrita Krishnan
MPMarcelo C Pasquini
Marcelo C Pasquini
BLBrent Logan
Brent Logan
ESEdward A Stadtmauer
Edward A Stadtmauer
DVDavid H Vesole
David H Vesole
DMDavid G Maloney
David G Maloney

1 July 2017 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
DVDan T. Vogl
Dan T. Vogl
NRNoopur Raje
Noopur Raje
SJSundar Jagannath
Sundar Jagannath
PRPaul Richardson
Paul Richardson
PHParameswaran Hari
Parameswaran Hari
SLSagar Lonial
Sagar Lonial
Purpose: Histone deacetylase (HDAC) inhibition improves the efficacy of proteasome inhibition for multiple myeloma but adds substantial toxicity. Preclinical models suggest that the observed synergy is due to the role of HDAC6 in mediating resistance to proteasome inhibition via the aggresome/autophagy pathway of protein degradation. Experimental Design: We conducted a phase I/II trial of the HDAC6-selective inhibitor ricolinostat to define the safety, preliminary efficacy, and recommended phase II dose in combination with standard proteasome inhibitor therapy. Patients with relapsed or refractory multiple myeloma received oral ricolinostat on days 1–5 and 8–12 of each 21-day cycle. Results: Single-agent ricolinostat therapy resulted in neither significant toxicity nor clinical responses. Combination therapy with bortezomib and dexamethasone was well-tolerated during dose escalation but led to dose-limiting diarrhea in an expansion cohort at a ricolinostat dose of 160 mg twice daily. Combination therapy at a ricolinostat dose of 160 mg daily in a second expansion cohort was well tolerated, with less severe hematologic, gastrointestinal, and constitutional toxicities compared with published data on nonselective HDAC inhibitors. The overall response rate in combination with daily ricolinostat at ≥160 mg was 37%. The response rate to combination therapy among bortezomib-refractory patients was 14%. Samples taken during therapy showed dose-dependent increases of acetylated tubulin in peripheral blood lymphocytes. Conclusions: At the recommended phase II dose of ricolinostat of 160 mg daily, the combination with bortezomib and dexamethasone is safe, well-tolerated, and active, suggesting that selective inhibition of HDAC6 is a promising approach to multiple myeloma therapy. Clin Cancer Res; 23(13); 3307–15. ©2017 AACR.